stockrow
Friday 6 November 2026
Export ELVN’s income statement to Excel — free account
Enliven Therapeutics, Inc.
ELVN Healthcare Biotechnology
- EPS
- 0.00%
- Free cash flow
- −8.34%
Quarter to June 2026, against a year earlier
48.63
3.84
+8.57%
Follow ELVN
Alert me
Enliven Therapeutics, Inc. (ELVN) Shares outstanding
Enliven Therapeutics, Inc.'s shares outstanding at the end of fiscal 2025 was $56.7M, up 20.4% from $47.1M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $66.2M. Over the past ten years it has ranged from $175.6K (fiscal 2019) to $56.7M (fiscal 2025) — the current reading is the highest in ten years. Enliven Therapeutics, Inc. ranks 227th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $56.7M | 20.38% |
| FY2024 | $47.1M | 32.43% |
| FY2023 | $35.5M | 1,037.73% |
| FY2022 | $3.1M | (42.31%) |
| FY2021 | $5.4M | 55.56% |
| FY2020 | $3.5M | 1,882.46% |
| FY2019 | $175.6K | (95.94%) |
| FY2018 | $4.3M | (75.00%) |
| FY2017 | $17.3M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $66.2M | 5.37% |
| Mar 2026 | $62.8M | 10.83% |
| Dec 2025 | $56.7M | (8.74%) |
| Sep 2025 | $62.1M | 19.17% |
| 26 more quarters | Free account |
Against its own ten years
Low $175.6K
High $56.7M
Ten-year median
$5.4M
Current reading's percentile
100
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| DNLI Denali Therapeutics Inc. compare | $192.1M |
| ACAD ACADIA Pharmaceuticals Inc. compare | $175.5M |
| DYN Dyne Therapeutics, Inc. compare | $165.5M |
| VKTX Viking Therapeutics, Inc. compare | $118.1M |
| VRDN Viridian Therapeutics, Inc. compare | $107.9M |
| ELVN Enliven Therapeutics, Inc. | $66.2M |
| CELC Celcuity, Inc. compare | $54.8M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $46.4M |
| TLX Telix Pharmaceuticals Limited compare | — |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item